Investor Overview

Corporate Profile
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >
Recent Newsmore >
February 16, 2017
Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
— AR101 Program to Initially Address Urgent Unmet Need of Peanut-Allergic Patients Ages 4-17, Consistent with Breakthrough Therapy Designation — — Potential BLA Filing to Include Safety Database of 600 Patients, Achievable with Current Phase 3 Program — — Conference Call Today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 16, 2017-- Aimmune Therapeutics, Inc. (Nasdaq... 
January 4, 2017
Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 35th Annual J.P. Morgan Healthcare Conferen... 
December 1, 2016
Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
— Five Leading Food Allergy Researchers and Clinicians Form Distinguished Board — BRISBANE, Calif.--(BUSINESS WIRE)--Dec. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced the membership of its Scientific Advisory Board, comprised of internationally recognized food allergy experts. ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.